## **Respiratory infection**

- Wilson EB, Livingstone AM. Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 2008;181:7445—8.
- de Bree GJ, Daniels H, Schilfgaarde M, et al. Characterization of CD4+ memory T cell responses directed against common respiratory pathogens in peripheral blood and lung. J Infect Dis 2007:195:1718—25.
- Barry SM, Lipman MC, Bannister B, et al. Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis 2003;187:243—50.
- Brenchley JM, Knox KS, Asher Al, et al. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol 2008;1:49—58.
- Jordano Q, Falcón V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;38:1623—8.
- Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005;191:150—8.
- Gordon SB, Malamba R, Mthunthama N, et al. Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine 2008;26:5400—6.
- Sallusto F, Lenig D, Főrster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999:401:708—12.
- Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
- Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009;180:1262—70.

- Bakocević N, Worbs T, Davalos-Misslitz A, et al. T cell-dendritic cell interaction dynamics during the induction of respiratory tolerance and immunity. J Immunol 2010;184:1317—27.
- Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003:17:1881—8.
- Kolte L, Gaardbo JC, Skogstrand K, et al. Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs. Clin Exp Immunol 2009;155:44—52.
- Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010:207:2869—81
- Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:441—6.
- Sutherland JS, Young JM, Peterson KL, et al. Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J Immunol 2010;184:6537—44.
- Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247—58.
- Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843—50.
- Forbes EK, Sander C, Ronan EO, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008;181:4955—64.
- Nebbia G, Mattes FM, Smith C, et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008;8:2590—9.

## Journal club

## MRSA colonisation may lead to increased mortality in patients with cystic fibrosis

The long-term impact of respiratory tract methicillin-resistant *Staphylococcus aureus* (MRSA) on cystic fibrosis (CF) outcomes is unclear. This cohort study used longitudinal data from the US CF registry between 1996 and 2008. The aim of the study was to assess whether acquisition of MRSA influenced mortality.

A total of 19833 MRSA negative patients aged 6–45 years were included in the study. Over the study period 5759 patients developed positive cultures for MRSA and there were 2537 deaths. The mortality rate was 27.7 deaths (95% CI 25.3 to 30.4) per 1000 patient-years in patients with MRSA and 18.3 deaths (95% CI 17.5 to 19.1) per 1000 patient-years in those without MRSA. After adjusting for variables associated with disease severity, the risk of death in patients positive for MRSA was higher than in patients who never cultured MRSA, with the greatest risk in patients chronically colonised with MRSA. Interestingly, patients who cleared MRSA within a year did not have an increased risk of death. No treatment or eradication data were described in the study.

This study provides convincing evidence that MRSA is an important pathogen in the CF airway. Questions remain about both the pathogenesis of MRSA infection and the optimal medical management in chronically infected patients. For now it is essential that strict infection control is in place to minimise transmission, and that eradication protocols are followed after a new identification.

▶ **Dasenbrook EC**, Checkley W, Merlo CA, *et al.* Association between respiratory tract methicillin-resistant *Staphylococcus aureus* and survival in cystic fibrosis. *JAMA* 2010;**303**:2386—92.

## **Paul Whitaker**

Correspondence to Paul Whitaker, SpR, St James's Hospital, Ward 2, Gledhow Wing, Leeds LS9 7TF, UK; paul.whitaker@leedsth.nhs.uk

Published Online First 21 October 2010

Thorax 2011;66:382. doi:10.1136/thx.2010.151290

382 Thorax May 2011 Vol 66 No 5